Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, responds to Allergan's recent transfer of patents to a soverign entity, and gives 2 takeaways for industry.
Transcript:
What can the industry learn from the response to Allergan’s recent transfer of patents to a sovereign entity?
I think they could learn 2 things. One, that folks will do just about anything to protect a blockbuster product. I’ve got to say that the lawyers who came up with that should get an award; I thought that was unbelievably creative. I guess the lesson is to expect anything.
The second thing folks can learn is that timing is everything. I thought the timing of this was awful. Drug pricing issues are swirling around, you’ve got Congress looking at it, you’ve got FDA looking at it, and to pull what I think can only be considered a stunt like this, it’s just awful timing for the industry. It might be good for the company that did it, but I think it plays very poorly with the regulators and policy makers.
It reminds me of something that happened probably 20 years ago in the Hatch-Waxman context where you had a similar atmosphere of criticism of the industry and criticism of some of the tactics that companies use to ward of generic competition, and just at that moment 1 big company got a new patent issued, and I think it was at 11:00 at night the day before generics were supposed to be approved, they submitted the patent to FDA and blocked generics for another 30 months. That set off a firestorm and actually prompted FTC to complain and FDA to change their regulations. Ultimately, it prompted Congress to step in and change the statute and address something like that.
I actually saw a lot of similarities between that situation and this situation, and I would not be surprised if you see some sort of legislative response to it.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.